Brentuximab Vedotin (ADCETRIS®)
About Brentuximab Vedotin
Brentuximab vedotin is an antibody-drug conjugate (ADC) that targets CD30, a defining marker of classical Hodgkin lymphoma (HL) using our proprietary auristatin-based technology. It comprises an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a cytotoxic (cell-killing) agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE when internalized into CD30-expressing tumor cells, resulting in target cell death.
We are developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the collaboration, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has commercialization rights in the rest of the world. The companies are funding joint worldwide development costs on a 50:50 basis, except in Japan where Takeda is fully responsible for development costs.
ADCETRIS® (brentuximab vedotin) is commercially available for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma in 65 countries, including the U.S., Canada, Japan and members of the European Union. In August 2015, the U.S. Food and Drug Administration expanded the U.S. label into a third indication as Hodgkin lymphoma post-autologous transplantation consolidation.
We are also conducting a comprehensive clinical development program in more than 70 corporate and investigator clinical trials, including three phase 3 studies designed to evaluate the potential of brentuximab vedotin in earlier lines of its approved indications as well as in many additional types of CD30-expressing lymphomas, including cutaneous T-cell lymphoma (CTCL), mature T-cell lymphomas (MTCL) and B-cell lymphomas.
These phase 3 clinical trials are ongoing:
- Phase 3 ALCANZA trial for CD30-expressing cutaneous T-cell lymphoma (data presented at ASH 2016)
- Phase 3 ECHELON-1 frontline Hodgkin lymphoma in combination with chemotherapy (enrollment complete)
- Phase 3 ECHELON-2 frontline CD30-expressing mature T-cell lymphomas in combination with chemotherapy (enrollment complete)